Mika Mizuno

ORCID

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 9

Top Venues

International journal of clinical oncology

Cytopathology : official journal of the British Society for Clinical Cytology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Journal of gynecologic oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Shintaro Yanazume, Kaori Iwakiri, Yusuke Kobayashi, Ikumi Kitazono, Toshiaki Akahane, Mika Mizuno, Shinichi Togami, Akihide Tanimoto, Hiroaki Kobayashi
Cytopathological features associated with POLE mutation in endometrial cancer. Cytopathology : official journal of the British Society for Clinical Cytology (2023)
Shintaro Yanazume, Kaori Iwakiri, Yusuke Kobayashi, Ikumi Kitazono, Toshiaki Akahane, Mika Mizuno, Shinichi Togami, Akihide Tanimoto, Shintaro Yanazume
Cytopathological features in the POLE mutation in endometrial cancer. Cytopathology : official journal of the British Society for Clinical Cytology (2023)
Shinichi Togami, Mika Fukuda, Mika Mizuno, Shintaro Yanazume, Hiroaki Kobayashi
Efficacy and prognosis of robotic surgery with sentinel node navigation surgery in endometrial cancer. Journal of gynecologic oncology (2023)
Mika Mizuno, Kimihiko Ito, Hidekatsu Nakai, Hidenori Kato, Shoji Kamiura, Kimio Ushijima, Shoji Nagao, Hirokuni Takano, Masao Okadome, Munetaka Takekuma, Hideki Tokunaga, Satoru Nagase, Daisuke Aoki, Robert L Coleman, Yasuko Nishimura, Christine K Ratajczak, Hideyuki Hashiba, Hao Xiong, Noriyuki Katsumata, Takayuki Enomoto, Aikou Okamoto
Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial. International journal of clinical oncology 28 (1) (2022)
Mika Mizuno, Kimihiko Ito, Hidekatsu Nakai, Hidenori Kato, Shoji Kamiura, Kimio Ushijima, Shoji Nagao, Hirokuni Takano, Masao Okadome, Munetaka Takekuma, Hideki Tokunaga, Satoru Nagase, Daisuke Aoki, Robert L Coleman, Yasuko Nishimura, Christine K Ratajczak, Hideyuki Hashiba, Hao Xiong, Noriyuki Katsumata, Takayuki Enomoto, Aikou Okamoto
Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial. International journal of clinical oncology 28 (1) (2022)
Mika Mizuno, Kimihiko Ito, Hidekatsu Nakai, Hidenori Kato, Shoji Kamiura, Kimio Ushijima, Shoji Nagao, Hirokuni Takano, Masao Okadome, Munetaka Takekuma, Hideki Tokunaga, Satoru Nagase, Daisuke Aoki, Robert L Coleman, Yasuko Nishimura, Christine K Ratajczak, Hideyuki Hashiba, Hao Xiong, Noriyuki Katsumata, Takayuki Enomoto, Aikou Okamoto
Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial. International journal of clinical oncology 28 (1) (2022)
Mika Mizuno, Kimihiko Ito, Hidekatsu Nakai, Hidenori Kato, Shoji Kamiura, Kimio Ushijima, Shoji Nagao, Hirokuni Takano, Masao Okadome, Munetaka Takekuma, Hideki Tokunaga, Satoru Nagase, Daisuke Aoki, Robert L Coleman, Yasuko Nishimura, Christine K Ratajczak, Hideyuki Hashiba, Hao Xiong, Noriyuki Katsumata, Takayuki Enomoto, Aikou Okamoto
Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial. International journal of clinical oncology 28 (1) (2022)
Mika Mizuno, Kimihiko Ito, Hidekatsu Nakai, Hidenori Kato, Shoji Kamiura, Kimio Ushijima, Shoji Nagao, Hirokuni Takano, Masao Okadome, Munetaka Takekuma, Hideki Tokunaga, Satoru Nagase, Daisuke Aoki, Robert L Coleman, Yasuko Nishimura, Christine K Ratajczak, Hideyuki Hashiba, Hao Xiong, Noriyuki Katsumata, Takayuki Enomoto, Aikou Okamoto
Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial. International journal of clinical oncology (2022)
Junzo Hamanishi, Nobuhiro Takeshima, Noriyuki Katsumata, Kimio Ushijima, Tadashi Kimura, Satoshi Takeuchi, Koji Matsumoto, Kimihiko Ito, Masaki Mandai, Hidekatsu Nakai, Sakuragi Noriaki, Hidemichi Watari, Nobutaka Takahashi, Hidenori Kato, Kosei Hasegawa, Kan Yonemori, Mika Mizuno, Kazuhiro Takehara, Hitoshi Niikura, Takashi Sawasaki, Sari Nakao, Toshiaki Saito, Takayuki Enomoto, Satoru Nagase, Nao Suzuki, Takashi Matsumoto, Asumi Okumura, Kenzo Sonoda, Satomi Aihara, Yoichi Aoki, Aikou Okamoto, Hirokuni Takano, Hiroshi Kobayashi, Hisamori Kato, Yoshito Terai, Akira Takazawa, Yusuke Takahashi, Yoshinobu Namba, Daisuke Aoki, Keiichi Fujiwara, Toru Sugiyama, Ikuo Konishi
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (33) (2021)

Mika Mizuno.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Mika Mizuno